South Africa joins seven nations in backing the IFFIm
- Press Releases
- South Africa joins seven nations in backing the IFFIm
South Africa joins seven nations in backing the IFFIm
25 April 2006
The Government of South Africa announced today that it will contribute US$20 million over 20 years to the International Finance Facility for Immunisation (IFFIm).
The Government of South Africa announced today that it will contribute US$20 million over 20 years to the International Finance Facility for Immunisation
Geneva, 25 April 2006 - The Government of South Africa announced today that it will contribute US$20 million over 20 years to the International Finance Facility for Immunisation (IFFIm).
South Africa joins Brazil and six European nations-France, Italy, Norway, Spain, Sweden and the United Kingdom-in supporting this innovative financing programme, which is expected to dramatically reduce the number of children who die every year from vaccine-preventable diseases in the world's poorest nations.
By raising capital against donor pledges over a ten-year period (through 2015), the IFFIm will yield an estimated US$4 billion of financing for immunisation. The new funds will support the work of the GAVI Alliance (formerly the Global Alliance for Vaccines and Immunisation), a leading global health partnership that includes developing country and donor governments, the World Health Organization (WHO), UNICEF, the World Bank, the vaccine industry in both industrialised and developing countries, and the Bill & Melinda Gates Foundation.
GAVI and its partners will use the new funding from the IFFIm to scale up efforts to provide millions more of the world's poorest children with access to life-saving vaccines, including through the strengthening of health systems.
The President of Brazil, Luiz Inacio Lula da Silva, announced in March that Brazil would contribute US$20 million over 20 years to support the IFFIm. The IFFIm is one of several recently announced innovative initiatives aimed at raising funds to reach the United Nations Millennium Development Goals.
With GAVI's support, a number of countries have improved their immunisation coverage rates and successfully introduced new vaccines, despite sometimes daunting economic and political obstacles. While GAVI funds can only be used for certain purposes, developing countries determine and drive their own plans for reaching their immunisation goals.
"Our experience suggests that development assistance can be particularly effective when we reward results, while at the same time providing flexibility in how the eligible countries reach established goals," said Dr. Julian Lob-Levyt, Executive Secretary of the GAVI Alliance. "And because the countries are delivering good results, donors have chosen to help GAVI scale up its activities through support for the IFFIm or through traditional annual contributions."
According to the World Health Organization (WHO), more than 1.7 million early deaths will have been prevented among residents of the poorest nations with the support GAVI provided in its first five years. Since 2001, the GAVI Alliance has made possible the purchase and distribution of enough doses of new-generation vaccines to immunise 115 million children. The WHO estimates that 225 million children will have been reached with these vaccines by the year 2008, protecting them against deadly diseases such as hepatitis b and yellow fever.
Dr. Lob-Levyt noted that the GAVI Alliance, in partnership with the World Bank, is also advising the G7 on developing a pilot for another financing programme - the Advance Market Commitments (AMCs). The goal of the AMCs is to ensure that the poorest countries have access to new vaccines when they become available, while providing the industry with incentives to invest in vaccines for poor countries, thus creating markets that resemble those of more affluent nations. An AMC for vaccines commits donors to subsidizing the future purchase (up to a pre-agreed price) of an appropriate vaccine, once it has been developed and once developing countries have requested it.
"There is an increasing awareness of the need for creative solutions in addressing the complex question of how best to cover the costs of developing and delivering new vaccines and other global health solutions," said Dr. Lob-Levyt. "These efforts will be crucial in reducing the death toll and in helping to reach the Millennium Development Goal for child survival. We are certain that the IFFIm is just the beginning."
###
The GAVI Alliance
An alliance of all the major stakeholders in immunisation, the GAVI Alliance includes among its partners developing country and donor governments, the World Health Organization (WHO), UNICEF, the World Bank, the vaccine industry in both industrialised and developing countries, research and technical agencies, NGOs, and the Bill & Melinda Gates Foundation. It is estimated that more than 1.7 million early deaths will have been prevented as a result of support by GAVI up to the end of 2005.
GAVI's efforts are critical to achieving the Millennium Development Goal on child health, which calls for reducing childhood mortality by two-thirds by 2015. Of the more than 10 million children who die before reaching their fifth birthday every year, 2.5 million die from diseases that could be prevented with currently available or new vaccines.
[Français]
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.
Reflections on IFFIm: an interview with Rachel Turner
14 November 2024